S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,669.61 -0.20%
Next Bullish Trade
Sign in
COR

Cencora, Inc. NYQ · COR

$307.90 -0.09 (-0.03%)
Extended · +1.60σ Grade C
Mkt cap $59.9B
P/E 23.6
Day $306.41 – $313.90
52wk $244.82 – $376.92
Avg vol 1.8M
Beta 0.58
Div yld 0.78%
Next earnings 2026-08-05

Quick read

Plain English

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.

COR last traded at $307.90, down 0.0% on the day; that's in the middle part of its 52-week range ($244.82–$376.92). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC2 upper, +1.54 ATR from EMA21 — no notable pattern

Long
score 12 · tech 12 / 80 · support 0 / 20
above KC1 lower, +1.54 ATR from EMA21 · no notable pattern
  • · Stochastic bull cross
How this grade was earned
total 12 pts
Cycle position 6
Momentum 3
Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short C
score 34 · tech 34 / 80 · support 0 / 20
KC2 upper, +1.54 ATR from EMA21 · no notable pattern
ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.
  • · KC2 upper stretch — standard mean-reversion tier
  • · RSI hook from overbought (64)
  • · Aligned with weak downtrend
How this grade was earned
total 34 pts
Cycle position 22
Momentum 6
Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 64), the trend is strong (ADX 28), and volume is about normal (1.4×). On the business side, revenue is growing 4% year over year and the business keeps about -0 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI
64
0–100 · <30 oversold
Trend strength · ADX
28
>25 = strong trend
Volume vs avg
1.43×
1× = average
Stretch from avg
+1.5 ATR
− below · + above
Zone touches
0
tests of this zone
Suggested hold
3–30
bars (≈ days)
Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth
+3.8%
year over year
Free-cash-flow margin
-0.1%
cash kept per $ of sales
Debt / equity
4.21
lower = less leveraged
P/E ratio
23.5
price ÷ yearly profit

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Fair-value range
$234.90 – $4954.73
Verdict
Unknown
Accounting quality Weak
  • ✓ Positive retained earnings
  • ⚠ Debt exceeds cash
  • ⚠ Quick ratio 0.47 (fragile)
  • ⚠ Debt/equity 49.63 (fragile)

Key statistics

All statistics →

COR is a $59.9 billion company, priced at 24× last year's earnings, and it moves more calmly than the market (beta 0.6).

Mkt cap $59.9B
P/E ttm 23.6
Fwd P/E 15.5
Beta 0.58
Day range $306.41 – $313.90
52w range $244.82 – $376.92
Avg vol 1.8M
RSI(2) 73.9
ROE 107.1%
Net mgn 0.8%
FCF mgn -0.1%
Debt/Eq 4.21
Div yld 0.78%
Sector Healthcare
Industry Medical Distribution
Next earn 2026-08-05
52-week range · today's price
$244.82$376.92

More on COR

Options idea

See more →
CALL $300 2026-08-21
$17.73
PUT $310 2026-08-21
$15.00

Earnings

See more →
Last reported
2026-05-06
EPS (act / est)
4.75 / 4.73
Surprise
+0.5%
Next report
2026-08-05

About

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail phar…